Physiological coagulation and wound-healing pathways

Physiological coagulation and wound-healing pathways are integrated biological processes essential for maintaining vascular integrity and repairing tissue damage [1, 2]. The process is initiated by hemostasis, where platelet activation and the coagulation cascade—a series of zymogen activations involving factors such as Thrombin and Factor Xa—result in the formation of a stable fibrin clot [3, 6]. This clot serves as a temporary matrix for the subsequent inflammatory, proliferative, and remodeling phases of wound healing [5, 7]. During these stages, various signaling molecules, including growth factors like Platelet-Derived Growth Factor (PDGF) and cytokines, coordinate the recruitment of immune cells, fibroblasts, and endothelial cells to the injury site [9, 12]. Dysregulation of these pathways can lead to significant clinical issues, such as excessive thrombosis, bleeding disorders like hemophilia, or the development of chronic, non-healing wounds [1, 10]. Pharmacological agents target these pathways in diverse ways, including anticoagulants that inhibit specific clotting enzymes to prevent stroke and embolism, and pro-healing agents like Becaplermin that stimulate cellular repair in diabetic ulcers [4, 5, 8]. Understanding the crosstalk between coagulation and tissue repair is critical for developing therapies that balance the prevention of thrombosis with the promotion of effective wound closure [11, 12].

Other names

HemostasisBlood coagulation cascadeWound healing cascadeClotting cascadeCoagulation and wound healing

Drugs targeting these pathways primarily act by inhibiting specific clotting factors (e.g., Factor Xa, Thrombin), preventing platelet aggregation, or stimulating cellular proliferation and migration through growth factor signaling [1, 4, 5, 8].